OncoSil Medical Gains Ethics Nod to Double Italian Hospital Network for Pancreatic Cancer Device

Central Ethics Approval Unlocks Italian Market Access

OncoSil Medical (ASX:OSL) has taken a significant step towards expanding its footprint in Italy by securing approval from the Comitato Etico Territoriale Lazio Area 4 ethics committee to reclassify its OSPRItaly patient registry as an observational clinical registry. This shift is more than a bureaucratic detail; it removes the need for separate ethics approvals at individual hospitals, smoothing the path for more centres to participate in the registry and adopt the OncoSil™ device for treating unresectable locally advanced pancreatic cancer (LAPC).

Streamlined Procurement and Reimbursement Framework

Crucially, the updated ethics approval enables hospitals to procure the OncoSil™ device directly via a negotiated procedure tendered process, sidestepping competitive bidding complexities. This streamlined procurement is expected to accelerate onboarding, with OncoSil Medical anticipating the addition of four more authorised hospitals over the next two quarters, effectively doubling its Italian treatment network by mid-2027. The reimbursement for the implantation procedure is now formally recognised within Italy's legal and regulatory framework, which should further incentivise hospital adoption and support commercial rollout.

Italy’s Pancreatic Cancer Market Opportunity

Italy represents a substantial European market, with over 16,000 new pancreatic cancer cases diagnosed annually. OncoSil Medical’s CEO Nigel Lange highlighted the strategic importance of this market, noting that the non-interventional classification of the registry not only simplifies purchasing but also signals growing clinical acceptance of the OncoSil™ device as part of routine care. This approval aligns with the company’s broader European expansion strategy, complementing recent regulatory and commercial milestones such as the TGA approval for OncoSil™ device in Australia and strong uptake reflected in the OSPREY registry interim results.

Building on Commercial Momentum

The Italian approval arrives amid a period of accelerating commercial activity for OncoSil Medical. The company recently reported a 60% year-on-year increase in dose sales, driven by expanding treatment centres across Europe and ongoing clinical trials. The simplified ethics and procurement framework in Italy could help sustain this momentum by facilitating faster hospital onboarding and patient access to the device. This is particularly important given the device’s targeted intratumoural radiation approach, which delivers higher radiation doses directly to tumours while sparing surrounding tissue, offering a distinct clinical advantage.